Index RUT
P/E -
EPS (ttm) -2.21
Insider Own 37.68%
Shs Outstand 80.50M
Perf Week 0.20%
Market Cap 2.20B
Forward P/E -
EPS next Y -1.55
Insider Trans -0.23%
Shs Float 53.90M
Perf Month 73.62%
Income -190.42M
PEG -
EPS next Q -0.53
Inst Own 62.01%
Short Float 10.85%
Perf Quarter 63.79%
Sales 174.91M
P/S 12.59
EPS this Y 9.17%
Inst Trans 1.28%
Short Ratio 3.40
Perf Half Y 107.92%
Book/sh 3.85
P/B 6.62
EPS next Y 25.59%
ROA -39.26%
Short Interest 5.85M
Perf Year 83.37%
Cash/sh 3.15
P/C 8.08
EPS next 5Y 21.00%
ROE -50.37%
52W Range 9.90 - 25.55
Perf YTD 57.90%
Dividend Est. -
P/FCF -
EPS past 5Y 4.07%
ROI -56.42%
52W High -0.31%
Beta 0.18
Dividend TTM -
Quick Ratio 3.94
Sales past 5Y 51.62%
Gross Margin 93.26%
52W Low 157.27%
ATR (14) 0.49
Dividend Ex-Date -
Current Ratio 4.19
EPS Y/Y TTM 5.92%
Oper. Margin -118.09%
RSI (14) 86.00
Volatility 0.15% 1.28%
Employees 355
Debt/Eq 0.08
Sales Y/Y TTM 26.51%
Profit Margin -108.86%
Recom 2.78
Target Price 26.30
Option/Short Yes / Yes
LT Debt/Eq 0.07
EPS Q/Q 14.02%
Payout -
Rel Volume 0.50
Prev Close 25.46
Sales Surprise 5.14%
EPS Surprise 6.91%
Sales Q/Q 34.55%
Earnings Feb 06 BMO
Avg Volume 1.72M
Price 25.47
SMA20 12.34%
SMA50 39.22%
SMA200 70.20%
Trades
Volume 851,175
Change 0.04%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-20-23 Resumed
JP Morgan
Neutral
$14
Oct-30-23 Upgrade
Piper Sandler
Neutral → Overweight
$23
Aug-10-23 Upgrade
Stifel
Hold → Buy
$14 → $20
Jan-04-23 Upgrade
Guggenheim
Neutral → Buy
$22
Aug-29-22 Initiated
Cowen
Outperform
$25
Aug-05-22 Upgrade
JMP Securities
Mkt Perform → Mkt Outperform
$23
Feb-28-22 Downgrade
Barclays
Equal Weight → Underweight
$11 → $6
Nov-08-21 Downgrade
Stifel
Buy → Hold
$60 → $10
Nov-08-21 Downgrade
Canaccord Genuity
Buy → Hold
$72 → $12
Nov-08-21 Downgrade
Barclays
Overweight → Equal Weight
$50 → $11
Nov-05-21 Downgrade
Truist
Buy → Hold
$65 → $10
Sep-30-21 Resumed
Stifel
Buy
$60
Mar-31-21 Initiated
Credit Suisse
Outperform
$78
Feb-10-21 Upgrade
SVB Leerink
Mkt Perform → Outperform
$70
Dec-03-20 Initiated
Stifel
Buy
$75
Sep-14-20 Resumed
JP Morgan
Neutral
$52
May-07-20 Downgrade
Nomura
Buy → Neutral
$84 → $60
Mar-04-20 Initiated
Barclays
Overweight
$70
Dec-20-19 Reiterated
Jefferies
Buy
$53 → $77
Oct-29-19 Upgrade
SVB Leerink
Underperform → Mkt Perform
$29 → $34
Show Previous Ratings
May-10-24 01:54PM
09:30AM
08:50AM
Apr-30-24 07:10AM
07:03AM
07:02AM
Loading…
07:02AM
07:00AM
03:41AM
Apr-29-24 02:36PM
02:17PM
01:41PM
01:02PM
(Pharmaceutical Technology)
12:17PM
12:16PM
11:19AM
10:46AM
Loading…
10:46AM
10:33AM
09:57AM
09:02AM
08:54AM
07:29AM
07:29AM
07:29AM
07:18AM
07:06AM
07:00AM
Apr-24-24 10:01AM
Apr-21-24 10:39AM
Apr-09-24 07:00AM
Mar-07-24 11:31AM
08:28PM
Loading…
Mar-04-24 08:28PM
Feb-28-24 09:55AM
Feb-27-24 07:00AM
Feb-12-24 09:55AM
Feb-07-24 09:20AM
08:28AM
12:33AM
(Thomson Reuters StreetEvents)
Feb-06-24 07:00AM
Feb-01-24 04:50PM
07:00AM
Jan-30-24 10:01AM
Jan-18-24 11:13AM
Jan-08-24 07:00AM
Jan-05-24 07:00AM
Jan-02-24 07:00AM
Dec-15-23 07:06AM
Dec-02-23 07:08AM
Nov-29-23 11:30AM
07:00AM
Nov-07-23 07:00AM
Nov-01-23 03:03AM
Oct-31-23 07:25AM
04:51AM
(Thomson Reuters StreetEvents)
01:16AM
Oct-30-23 08:15AM
07:01AM
07:00AM
Oct-16-23 12:39PM
Oct-05-23 11:38AM
Sep-29-23 09:00AM
Sep-22-23 12:02PM
11:46AM
Sep-15-23 05:00PM
Sep-08-23 11:30AM
Aug-21-23 07:43PM
Aug-19-23 07:40AM
Aug-18-23 04:05PM
Aug-11-23 03:30PM
Aug-10-23 08:13AM
Aug-09-23 08:50AM
07:00AM
Aug-03-23 04:15PM
Aug-02-23 07:00AM
Jun-09-23 09:02AM
Jun-02-23 11:31AM
May-25-23 05:00PM
May-23-23 07:00AM
May-08-23 01:31PM
07:00AM
May-04-23 05:38AM
May-03-23 08:15AM
07:00AM
Apr-27-23 10:03AM
Apr-26-23 10:02AM
07:00AM
Apr-19-23 07:00AM
Apr-18-23 06:53AM
Mar-23-23 11:30AM
Mar-16-23 05:25PM
Mar-15-23 11:52AM
06:28AM
Mar-14-23 05:53PM
05:32PM
04:26AM
Mar-09-23 11:30AM
Mar-01-23 07:00AM
Feb-27-23 07:00AM
Feb-08-23 02:13PM
08:43AM
05:40AM
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company was founded by Peter A. Petillo and Daniel L. Flynn in 2003 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Kelly Thomas Patrick Chief Financial Officer Feb 16 '24 Sale 15.62 3,010 47,009 80,350 Feb 20 04:05 PM Sherman Matthew L EVP & Chief Medical Officer Feb 16 '24 Sale 15.62 2,615 40,840 108,739 Feb 20 04:06 PM Pitman Jama SVP, Chief Development Officer Feb 16 '24 Sale 15.62 2,267 35,405 68,031 Feb 20 04:05 PM Martin Daniel C. Chief Commercial Officer Feb 16 '24 Sale 15.62 2,267 35,405 55,118 Feb 20 04:05 PM Kelly Thomas Patrick Chief Financial Officer Jan 16 '24 Sale 14.47 2,435 35,234 66,085 Jan 18 04:15 PM Sherman Matthew L EVP & Chief Medical Officer Jan 16 '24 Sale 14.47 2,435 35,234 94,079 Jan 18 04:15 PM Pitman Jama SVP, Chief Development Officer Jan 16 '24 Sale 14.47 1,624 23,499 50,573 Jan 18 04:15 PM Martin Daniel C. Chief Commercial Officer Jan 16 '24 Sale 14.47 1,624 23,499 47,660 Jan 18 04:15 PM Hoerter Steven L. President and CEO Dec 13 '23 Sale 15.37 30,664 471,217 72,763 Dec 14 04:05 PM Kelly Thomas Patrick Chief Financial Officer Dec 13 '23 Sale 15.37 2,792 42,905 68,520 Dec 14 04:05 PM Sherman Matthew L EVP & Chief Medical Officer Dec 13 '23 Sale 15.37 2,792 42,905 96,514 Dec 14 04:05 PM Martin Daniel C. Chief Commercial Officer Dec 13 '23 Sale 15.37 1,727 26,539 49,284 Dec 14 04:05 PM Pitman Jama See Remarks Dec 13 '23 Sale 15.37 1,662 25,540 52,197 Dec 14 04:05 PM Martin Daniel C. Chief Commercial Officer Nov 30 '23 Sale 12.57 17,801 223,755 45,435 Dec 01 04:05 PM Hoerter Steven L. President and CEO Oct 30 '23 Sale 12.02 21,573 259,256 40,927 Oct 31 04:09 PM Sherman Matthew L EVP & Chief Medical Officer Oct 30 '23 Sale 12.02 2,360 28,362 90,628 Oct 31 04:11 PM Kelly Thomas Patrick Chief Financial Officer Oct 30 '23 Sale 12.02 2,316 27,833 63,068 Oct 31 04:09 PM Martin Daniel C. Chief Commercial Officer Oct 30 '23 Sale 12.02 1,407 16,909 62,884 Oct 31 04:10 PM Pitman Jama See Remarks Oct 30 '23 Sale 12.02 1,407 16,909 48,283 Oct 31 04:10 PM Sherman Matthew L EVP & Chief Medical Officer Oct 02 '23 Sale 12.68 2,942 37,305 84,744 Oct 04 04:05 PM Kelly Thomas Patrick Chief Financial Officer Jun 16 '23 Sale 14.40 1,655 23,835 57,140 Jun 21 04:05 PM Sherman Matthew L EVP & Chief Medical Officer Jun 16 '23 Sale 14.40 1,655 23,835 87,686 Jun 21 04:05 PM Flynn Daniel Lee Chief Scientific Officer Jun 16 '23 Sale 14.40 1,655 23,835 57,158 Jun 21 04:05 PM Martin Daniel C. Chief Commercial Officer Jun 16 '23 Sale 14.40 1,238 17,829 58,413 Jun 21 04:05 PM Pitman Jama See Remarks Jun 16 '23 Sale 14.40 1,238 17,829 43,812 Jun 21 04:05 PM Friedman Franklin Stuart Director Jun 08 '23 Buy 13.88 10,000 138,828 10,000 Jun 12 04:05 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite